New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma.
Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe drugs.
Able to provide written informed consent.
Has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan).
Common Terminology Criteria for Adverse Events (CTCAE) Grade IV end organ dysfunction (i.e., hepatic, renal, gastrointestinal).
Had previous oncological treatment (not first cancer diagnosis).
Is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent.
Any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent.
Unable to provide written informed consent.
Clareo Health | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
